Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
van der Noordaa MEM, van Duijnhoven FH, Cuijpers FNE, van Werkhoven E, Wiersma TG, Elkhuizen PHM, Winter-Warnars G, Dezentje V, Sonke GS, Groen EJ, Stokkel M, Vrancken Peeters MTFD. van der Noordaa MEM, et al. Among authors: elkhuizen phm. Br J Surg. 2021 Jun 22;108(6):667-674. doi: 10.1002/bjs.12026. Br J Surg. 2021. PMID: 34157085
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
van Loevezijn AA, van der Noordaa MEM, Stokkel MPM, van Werkhoven ED, Groen EJ, Loo CE, Elkhuizen PHM, Sonke GS, Russell NS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: elkhuizen phm. Breast Cancer Res Treat. 2022 May;193(1):37-48. doi: 10.1007/s10549-022-06545-z. Epub 2022 Mar 3. Breast Cancer Res Treat. 2022. PMID: 35239072 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 33031572
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, Schinagl D, Oei B, Rodenhuis CC, Horiot JC, Struikmans H, Van Limbergen E, Kirova Y, Elkhuizen P, Bongartz R, Miralbell R, Morgan DA, Dubois JB, Remouchamps V, Mirimanoff RO, Hart G, Collette S, Collette L, Bartelink H; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Breast Cancer Groups. Vrieling C, et al. Among authors: elkhuizen p. JAMA Oncol. 2017 Jan 1;3(1):42-48. doi: 10.1001/jamaoncol.2016.3031. JAMA Oncol. 2017. PMID: 27607734 Clinical Trial.
A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients.
Bosma SCJ, Hoogstraat M, van Werkhoven E, de Maaker M, van der Leij F, Elkhuizen PHM, Fourquet A, Poortmans P, Boersma LJ, Bartelink H, van de Vijver MJ; Young Boost Trial research group. Bosma SCJ, et al. Among authors: elkhuizen phm. Radiother Oncol. 2021 Mar;156:127-135. doi: 10.1016/j.radonc.2020.11.025. Epub 2020 Nov 24. Radiother Oncol. 2021. PMID: 33245949 Clinical Trial.
Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy.
van Aken ESM, Beeker A, Houtenbos I, Pos FJ, Linn SC, Elkhuizen PHM, de Jong MC. van Aken ESM, et al. Among authors: elkhuizen phm. Cancer Rep (Hoboken). 2022 Feb;5(2):e1470. doi: 10.1002/cnr2.1470. Epub 2021 Jun 18. Cancer Rep (Hoboken). 2022. PMID: 34145976 Free PMC article.
55 results